Braveheart Investment (GB:BRH) has released an update.
Braveheart Investment Group has announced updates on two key portfolio companies, Kirkstall and Paraytec. Kirkstall has expanded its reach in the Chinese market with a new exclusive distribution agreement for its Quasi Vivo products, aimed at reducing the need for animal testing in drug safety assessments. Meanwhile, Paraytec has patented a method that significantly accelerates bacteria detection in human blood, offering potential for future royalty income through licensing to other manufacturers.
For further insights into GB:BRH stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “Be the Leader You’ve Been Complaining For!” Paramount Stock (NASDAQ:PARA) Dips as Paramount Pulls Out of Politics
- Don’t “Get Rid of All Your Engine Designers”: Ford Stock (NYSE:F) Dips as it Brings Back a Big Name in Internal Combustion
- “Advanced Silicon Wafer Tests” Start; Intel Stock (NASDAQ:INTC) Slips